Rho Cancer Research Results

Rho, Rho GTPases: Click to Expand ⟱
Source:
Type:
The Rho GTPases RhoA, Rac1, and Cdc42 are important regulators of cytoskeletal dynamics. small GTPase Ras homolog gene family member A (RHOA)
RHOA: Ras homolog family member A
Many in vitro and in vivo data indicate tumor-promoting effects of activated Rho GTPases, also tumor suppressive functions have been described.
In many cancers, RhoA and RhoC are often found to be overexpressed.
RhoB expression can be downregulated in certain cancers, which may contribute to tumor progression. Unlike RhoA and RhoC, RhoB is often considered a tumor suppressor, and its loss can lead to increased cell proliferation and survival.
-RhoA activity has been linked to the modulation of EMT, influencing both the disassembly of cell–cell junctions and the reorganization of the cytoskeleton necessary for migration.
-Elevated levels or hyperactivation of RhoA has been associated with poor prognosis in several cancers.


Scientific Papers found: Click to Expand⟱
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1/CCL2↓, PGE2↓, COX2/PTGS2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2/PTGS2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
746- Bor,    Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope
- Review, NA, NA
eff↑, *toxicity↓, ROS↑, LAT↓, AntiCan↑, AR↓, PSMB5↓, IGF-1↓, PSA↓, TumVol↓, eff↑, Rho↓, Cdc42↓, Ca+2↓, eff↑,
757- Bor,    Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration
- in-vitro, Pca, DU145 - in-vitro, Nor, RWPE-1
Rho↓, Rac1↓, Cdc42↓, *eff↑,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2/PTGS2↓, NF-kB↓, PDK1 / PDPK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
2974- CUR,    Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, HCT15 - in-vitro, CRC, COLO205 - in-vitro, CRC, SW-620 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumCG↓, TumMeta↓, Sp1/3/4↓, HDAC4↓, FAK↓, CD24↓, E-cadherin↑, EMT↓, TumCP↓, NF-kB↓, AP-1↝, STAT3↓, P53?, β-catenin/ZEB1↓, NOTCH1↝, Hif1a↝, PPARα↝, Rho↓, MMP2↓, MMP9↓,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1/ATG6↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2/KDR/Flk1↓, IAP2/BIRC3↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
2882- HNK,    Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling
- in-vitro, PC, PANC1
TumCI↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, Snail↓, Slug↓, Rho↓, ROCK1↓,
8075- KAE,  QC,    Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies
- Review, Var, NA
tumCV↓, Apoptosis↑, TumCP↓, TumCMig↓, PI3K↓, Akt↓, MAPK↓, NF-kB↓, P53↑, Bcl-2↓, PARP↑, ERK↓, IQGAP3↓, γH2AX↑, cl‑Casp3↑, cl‑Casp9↑, Rho↓, Rac1↓, MMP2↓, MMP9↓, CTSB↓, CTSD↓, O-Glc↓, SERPINH1/HSP47↓, EMT↓, angioG↓, EGF↓, VEGFR2/KDR/Flk1↓, RadioS↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP/DDIT3↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
1713- Lyco,    Lycopene: A Potent Antioxidant with Multiple Health Benefits
- Review, Nor, NA
*antiOx↑, *ROS⇅, *Dose↝, *eff↑, *LDL↓, *RenoP↑, *Inflam↓, neuroP↑, Rho↓,
205- MFrot,  MF,    Intermittent F-actin Perturbations by Magnetic Fields Inhibit Breast Cancer Metastasis
- vitro+vivo, BC, MDA-MB-231
OS↑, F-actin↓, TumCI↓, TumCMig↓, Rho↓, selectivity↑, TumMeta↓,
5187- PEITC,    Phenethyl Isothiocyanate Inhibits Migration and Invasion of Human Gastric Cancer AGS Cells through Suppressing MAPK and NF-κB Signal Pathways
- in-vitro, GC, AGS
TumMeta↓, ERK↓, MKK7↓, PKCδ↓, Rho↓, uPA↓, MMP2↓, MMP9↓, RAS↓, VEGF↓, FAK↓, iNOS↓, COX2/PTGS2↓, TumCP↓,
3083- RES,    Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
YAP/TEAD↓, Rho↓, FAK↓, MMP9↓, ChemoSen↑, RAS↓, ROCK1↓, TumCI↓, TumMeta↓,
1818- VitK2,    New insights on vitamin K biology with relevance to cancer
- Review, Var, NA
TumCG↓, ChemoSen↑, toxicity∅, OS↑, BMD↑, eff↑, MMP↓, ROS↑, eff↓, ERK↑, JNK↑, p38↑, Cyt‑c↑, Casp↑, ATP↓, lactateProd↑, AMPK↑, Rho↓, TumCG↓, BioAv↑, cardioP↑, Risk↓,

Showing Research Papers: 1 to 14 of 14

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 14

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

IQGAP3↓, 1,   O-Glc↓, 1,   SERPINH1/HSP47↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   CYP1A1↓, 1,   GPx↓, 1,   GSH↓, 2,   GSR↓, 1,   GSTs↓, 1,   HO-1↓, 1,   lipid-P↑, 1,   NQO1↓, 1,   NRF2↓, 2,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 7,   mt-ROS↑, 1,   SOD↓, 1,   SOD2↓, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   ATP↓, 1,   mt-ATP↓, 1,   CDC2↓, 1,   CDC25↓, 3,   EGF↓, 1,   MKK7↓, 1,   MMP↓, 3,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 2,   cMyc↓, 1,   Glycolysis↓, 1,   lactateProd↑, 1,   LAT↓, 1,   PCK1↓, 1,   PDK1 / PDPK1↓, 1,   PDK3↑, 1,   PPARα↝, 1,   PSMB5↓, 1,   SIRT1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   p‑Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 2,   Bcl-2↓, 4,   Bcl-xL↓, 1,   Casp↑, 3,   Casp1↓, 1,   Casp3↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp8↑, 2,   Casp9↑, 1,   cl‑Casp9↑, 1,   Chk2↑, 1,   Cyt‑c↑, 4,   Diablo↑, 1,   DR5↑, 2,   Fas↑, 3,   FasL↑, 2,   HGF/c-Met↓, 1,   IAP1↓, 1,   IAP2/BIRC3↓, 1,   iNOS↓, 1,   JNK↑, 1,   p‑JNK↑, 1,   MAPK↓, 4,   MDM2↓, 1,   p‑MDM2↓, 1,   p38↑, 1,   p‑p38↓, 1,   p‑p38↑, 1,   survivin↓, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

H3↓, 1,   p‑H3↓, 1,   H4↓, 1,   other↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1/ATG6↑, 1,   LC3II↑, 2,   LC3s↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 2,   CHK1↑, 1,   P53?, 1,   P53↑, 2,   PARP↑, 2,   cl‑PARP↑, 1,   PCNA↓, 3,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 2,   CDK4↓, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 1,   RB1↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD24↓, 1,   CD34↓, 1,   cFos↑, 1,   CTSB↓, 1,   CTSD↓, 1,   EMT↓, 5,   EMT↑, 1,   ERK↓, 3,   ERK↑, 1,   GSK‐3β↑, 1,   HDAC↓, 1,   HDAC4↓, 1,   IGF-1↓, 1,   mTOR↓, 3,   mTORC1↓, 1,   mTORC2↓, 1,   NOTCH1↓, 1,   NOTCH1↑, 1,   NOTCH1↝, 1,   PI3K↓, 2,   p‑PI3K↓, 1,   PTEN↓, 1,   RAS↓, 4,   p‑Src↓, 1,   STAT3↓, 4,   p‑STAT6↓, 1,   TOP1↓, 1,   TumCG↓, 3,  

Migration(tgid=13) ⓘ

AP-1↝, 1,   AXL↓, 1,   Ca+2↓, 1,   Ca+2↑, 1,   Cdc42↓, 3,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 3,   F-actin↓, 1,   FAK↓, 5,   p‑FAK↓, 1,   ITGB1↓, 1,   Ki-67↓, 2,   MET↓, 1,   p‑MET↓, 1,   MMP1↓, 1,   MMP13↓, 2,   MMP2↓, 5,   MMP3↓, 1,   MMP7↓, 1,   MMP9↓, 5,   MMP9↑, 1,   MMPs↓, 1,   N-cadherin↓, 2,   PKCδ↓, 1,   Rac1↓, 3,   Rho↓, 14,   ROCK1↓, 4,   Slug↓, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   Snail↓, 2,   TGF-β↓, 1,   TumCI↓, 5,   TumCMig↓, 4,   TumCP↓, 4,   TumMeta↓, 6,   Tyro3↓, 1,   uPA↓, 4,   Vim↓, 1,   Vim↑, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   EGFR↑, 1,   Hif1a↝, 1,   VEGF↓, 4,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   CD4+↓, 1,   COX2/PTGS2↓, 4,   ICAM-1↓, 1,   IKKα↓, 1,   IL1↓, 1,   IL1β↓, 1,   IL2↑, 2,   IL6↓, 2,   Inflam↓, 1,   JAK1↓, 1,   MCP1/CCL2↓, 1,   NF-kB↓, 7,   p‑p65↓, 1,   PD-1↓, 1,   PD-L1↓, 1,   PGE2↓, 1,   PSA↓, 1,   TNF-α↓, 3,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 3,   ChemoSen↑, 4,   Dose↝, 1,   eff↓, 1,   eff↑, 7,   Half-Life↓, 2,   RadioS↑, 2,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 3,   BMD↑, 1,   CEA↓, 1,   EGFR↑, 1,   IL6↓, 2,   Ki-67↓, 2,   NSE↓, 1,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   cachexia↓, 1,   cardioP↑, 1,   chemoP↑, 2,   hepatoP↑, 1,   neuroP↑, 2,   OS↑, 2,   RenoP↑, 2,   Risk↓, 1,   toxicity∅, 1,   TumVol↓, 1,  
Total Targets: 233

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↑, 3,   GPx↑, 3,   GSH↑, 1,   GSTs↑, 1,   lipid-P↓, 1,   MDA↓, 1,   ROS↓, 2,   ROS⇅, 1,   SOD↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL10↑, 1,   IL1β↓, 1,   Inflam↓, 3,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 3,   Half-Life↝, 1,  

Functional Outcomes(tgid=23) ⓘ

hepatoP↑, 1,   neuroP↑, 1,   RenoP↑, 1,   toxicity↓, 1,  
Total Targets: 23

Scientific Paper Hit Count for: Rho, Rho GTPases
2 Boron
1 Berberine
1 Chrysin
1 Propolis -bee glue
1 Curcumin
1 Fisetin
1 Honokiol
1 Kaempferol
1 Quercetin
1 Luteolin
1 Lycopene
1 Magnetic Field Rotating
1 Magnetic Fields
1 Phenethyl isothiocyanate
1 Resveratrol
1 Vitamin K2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:273  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page